Spring 2025
Oligonucleotides and Peptides
Peptide drugs recorded global sales in Europe. The market for gene and cell therapy contract manufacturing, oligonucleotide synthesis and the production of viral vectors and plasmids is also expanding considerably. But there is still plenty of room for technological improvement.
Peptide drugs such as the glucagon-like peptide-1 (GLP-1) receptor agonists semaglutide and tirzepatide alone recorded global sales of US$25.3bn in 2024, US$9.62bn of which in Europe. The market for gene and cell therapy contract manufacturing, oligonucleotide synthesis (US$9.1bn) and the production of viral vectors and plasmids (US$3.3bn), which is currently growing at an annual rate of 27%, is also expanding considerably. But there is still plenty of room for technological improvement.
In this Special:
- Towards a LNA-ASO-based obesity gene therapy – Just before going into Phase I testing, Italian Resalis Therapeutics srl has secured €10m in a Series A financing and an equity investment of Sanofi SA. European Biotechnology spoke with Alessandro Toniolo, CEO of Resalis, about the challenges to commercialise an obesity gene therapy targeting miRNA 22.
- Enhancing macromolecule drug discovery with CDD
- Making AAV gene therapy faster and better
- Precision oligonucleotides for therapeutics
